Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

690 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Thromboembolism and Adjuvant Endocrine Therapy (AET) in Hormone Receptor-Positive Early Breast Cancer (EBC): Did Treatment Evolution Change Incidence of the Adverse Event? A Meta-Analysis.
D'Onofrio R, Sperduti I, Piacentini F, Barbolini M, Omarini C, Toss A, Cortesi L, Barbieri E, Canino F, Dominici M, Moscetti L. D'Onofrio R, et al. Among authors: barbieri e. Clin Breast Cancer. 2023 Dec;23(8):e534-e541. doi: 10.1016/j.clbc.2023.09.002. Epub 2023 Sep 9. Clin Breast Cancer. 2023. PMID: 37775349 Review.
Adjuvant Endocrine Therapy in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer: Risk Stratification in a Real-World Setting.
D'Onofrio R, Omarini C, Toss A, Sperduti I, Piacentini F, Barbolini M, Cortesi L, Barbieri E, Pettorelli E, Chiavelli C, Dominici M, Moscetti L. D'Onofrio R, et al. Among authors: barbieri e. Clin Breast Cancer. 2023 Oct;23(7):712-720.e3. doi: 10.1016/j.clbc.2023.06.013. Epub 2023 Jul 7. Clin Breast Cancer. 2023. PMID: 37507257
Personalized Systemic Therapies in Hereditary Cancer Syndromes.
Mastrodomenico L, Piombino C, Riccò B, Barbieri E, Venturelli M, Piacentini F, Dominici M, Cortesi L, Toss A. Mastrodomenico L, et al. Among authors: barbieri e. Genes (Basel). 2023 Mar 9;14(3):684. doi: 10.3390/genes14030684. Genes (Basel). 2023. PMID: 36980956 Free PMC article. Review.
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial.
Guerra L, Chauvie S, Fallanca F, Bergesio F, Marcheselli L, Durmo R, Peano S, Franceschetto A, Monaco L, Barbieri E, Ladetto M, Musuraca G, Tosi P, Bianchi B, Bolis SAM, Pavone V, Chiarenza A, Arcari A, Califano C, Bari A, Massaia M, Conconi A, Musto P, Mannina D, Roti G, Galimberti S, Gini G, Falcinelli F, Vitolo U, Usai SV, Stefani PM, Ibatici A, Liberati AM, Pennese E, Perrone T, Versari A, Luminari S; Fondazione Italiana Linfomi (FIL). Guerra L, et al. Among authors: barbieri e. Eur J Nucl Med Mol Imaging. 2024 May 25. doi: 10.1007/s00259-024-06765-z. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38795120
690 results